Base de dados : LILACS
Pesquisa : D12.776.624 [Categoria DeCS]
Referências encontradas : 123 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 123 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-889036
Autor: Zhang, X; Song, Y; Song, N; Zhang, L; Wang, Y; Li, D; Wang, Z; Qu, X; Liu, Y.
Título: Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;51(3):e6265, 2018. tab, graf.
Idioma: en.
Projeto: National Science and Technology Major Project; . Science and Technology Plan Project; . Chinese National Foundation of National Sciences; . Liaoning BaiQianWan Talents Program.
Resumo: The receptor activator of nuclear factor κB ligand (RANKL)/RANK pathway plays an important role in the prognosis of several solid tumor types, but its role in gastric cancer prognosis has been poorly characterized. A total of 116 gastric cancer patients who underwent surgical resection were enrolled in this study. Expressions of RANKL and RANK in gastric cancer tissues were detected using immunohistochemical staining. Thirty-eight patients (33%) showed a high level of RANKL expression and 61 patients (53%) showed a high level of RANK expression. There was a positive correlation between expressions of RANKL and RANK (P=0.014, r=0.221). A high level of RANKL expression indicated shorter overall survival (OS) (P=0.008), and was associated with a higher pathological tumor/lymph node/metastasis (pTNM) stage (P=0.035), while no significant correlation was detected between RANK expression and clinicopathological parameters. RANKL also predicted poor prognosis in patients with high RANK expression (P=0.008) and Bormann's type III/IV (P=0.002). Furthermore, RANKL expression correlated with pTNM stage according to high RANK expression (P=0.009), while no significance was found in patients with low RANK expression (P=1.000). Together, our results revealed that high expression of RANKL could predict worse outcomes in gastric cancer especially combined with RANK detection, and thereby this pathway could be a useful prognostic indicator of gastric cancer.
Descritores: Adenocarcinoma/metabolismo
Proteínas de Neoplasias/metabolismo
Ligante RANK/metabolismo
Neoplasias Gástricas/metabolismo
-Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Adenocarcinoma/cirurgia
China/epidemiologia
Regulação Neoplásica da Expressão Gênica
Imuno-Histoquímica
Gradação de Tumores
Estadiamento de Neoplasias
Prognóstico
Estudos Retrospectivos
Estatísticas não Paramétricas
Neoplasias Gástricas/mortalidade
Neoplasias Gástricas/patologia
Neoplasias Gástricas/cirurgia
Limites: Seres Humanos
Masculino
Feminino
Meia-Idade
Responsável: BR1.1 - BIREME


  2 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-870854
Autor: Sousa, Gabriela Resende Vieira de.
Título: Análise dos genes DICER1 e TARBP2 em tumores do córtex da suprarrenal de crianças e adultos / DICER1 and TARBP2 gene analysis in adult and pediatric adrenocortical tumors.
Fonte: São Paulo; s.n; 2015. [146] p. ilus, tab, graf.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Medicina para obtenção do grau de Doutor.
Resumo: INTRODUÇÃO: O carcinoma cortical da suprarrenal é uma neoplasia rara com uma incidência estimada em 0,5-2,0 por milhão por ano em adultos. No momento, poucas opções terapêuticas para os pacientes com doença metastática são disponíveis, e novas descobertas sobre a sua patogênese são necessárias. O perfil de expressão gênica dos microRNAs (miRNAs) em tumores humanos tem sido caracterizado por uma redução global da expressão dos miRNAs. A enzima DICER1 e seu cofator TRBP (codificado pelo gene TARBP2) estão envolvidos em uma etapa essencial do processamento dos miRNAs. De forma interessante, a desregulação do processamento dos miRNAs em células cancerosas devido ao silenciamento da DICER1 propiciou a emergência de células com fenótipo mais agressivo, acelerando a progressão tumoral. Recentemente, mutações somáticas missense recorrentes no domínio de clivagem RNase IIIb da enzima DICER1 foram identificadas em 29% tumores de ovários não-epiteliais esteroidogênicos (e em até 60% de tumores ovarianos de células de Leydig). Adicionalmente, mutações inativadoras no éxon 5 do gene TARBP2, com consequente prejuízo da função da DICER1, foram identificadas em linhagens celulares de tumores com instabilidade cromossômica. OBJETIVOS: Determinar a expressão gênica e proteica da DICER1 e TRBP em tumores do córtex da suprarrenal de adultos e crianças; Investigar variantes genéticas no domínio de clivagem RNAse IIIb do gene DICER1; Investigar variantes genéticas no éxon 5 do gene TARBP2; Estudar a expressão dos miR-103 e miR-107, envolvidos na regulação da DICER1, e do miR-497, envolvido na regulação da TRBP. MÉTODOS: A expressão proteica da DICER1 e da TRBP foi avaliada por imunohistoquímica em uma micromatriz tecidual contendo 198 tumores do córtex da suprarrenal [154 em adultos (75 adenomas e 79 carcinomas) e 44 em crianças (38 clinicamente benignos e 6 clinicamente malignos)]. A expressão gênica da DICER1 e TARBP2 foi avaliada em um subgrupo de 84...

INTRODUCTION: Adrenocortical cancer is a rare neoplasia with an estimated incidence of 0.5-2.0/million/year in adults. There are currently few therapeutic options for patients with adrenocortical cancer, and new insights into the pathogenesis of this lethal disease are needed. The microRNA (miRNA) expression profile of human tumors has been characterized by an overall miRNA downregulation. DICER1 enzyme and its cofactor TRBP are a key component of the miRNA processing machinery. It was recently demonstrated that escaping miRNA control in cancer cells due to Dicer downregulation may allow the phenotypic emergence of more aggressive genetic variants, accelerating cancer progression. Recently, DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors, predominantly in Sertoli-Leydig cell tumors (60%). In addition, TARBP2 truncating mutations, causing DICER1 destabilization, were identified in tumor cell lines with microsatellite instability. AIM: To study the mRNA and protein expression of DICER1 and TRBP in adult and pediatric adrenocortical tumors; To investigate DICER1 mutations in metal biding sites located at the RNase IIIb domain; To investigate inactivating mutations in the exon 5 of TARBP2 gene; To determine the expression of miR-103 and miR-107, DICER1 regulators, and miR-497, a TRBP regulator. METHODS: Protein expression of DICER1 and TRBP was evaluated by immunohistochemistry in a tissue microarray with 198 adrenocortical tumors [154 in adults (75 adenomas and 79 carcinomas) and 44 in children (38 clinically benign and 6 malignant)]. Expression of DICER1 and TARBP2 genes was assessed in a subgroup of 84 tumors (61 adults and 23 children) and miRNA expression in 82 tumors (59 adults and 23 children). The DICER1 and TARBP2 gene sequencing was performed in a subgroup of 83 tumors. RESULTS: In adults, a strong DICER1 expression was demonstrated in 39 out of 79 carcinomas (51%) and in 24 out of 75 adenomas...
Descritores: Carcinoma Adrenocortical
Carcinogênese
Expressão Gênica
Regulação Neoplásica da Expressão Gênica
MicroRNAs
Biomarcadores Tumorais
Proteínas de Neoplasias
Prognóstico
Sobrevida
Limites: Seres Humanos
Masculino
Feminino
Criança
Adulto
Responsável: BR66.1 - Divisão de Biblioteca e Documentação
BR66.1


  3 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-839243
Autor: Zhao, L M; Pang, A X.
Título: Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-kappaB pathways
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;50(1):e5933, 2017. graf.
Idioma: en.
Resumo: Iodine-131 (131I) is widely used for the treatment of thyroid-related diseases. This study aimed to investigate the expression of p53 and BTG2 genes following 131I therapy in thyroid cancer cell line SW579 and the possible underlying mechanism. SW579 human thyroid squamous carcinoma cells were cultured and treated with 131I. They were then assessed for 131I uptake, cell viability, apoptosis, cell cycle arrest, p53 expression, and BTG2 gene expression. SW579 cells were transfected with BTG2 siRNA, p53 siRNA and siNC and were then examined for the same aforementioned parameters. When treated with a JNK inhibitor of SP600125 and 131I or with a NF-κB inhibitor of BMS-345541 and 131I, non-transfected SW579 cells were assessed in JNK/NFκB pathways. It was observed that 131I significantly inhibited cell proliferation, promoted cell apoptosis and cell cycle arrest. Both BTG2 and p53 expression were enhanced in a dose-dependent manner. An increase in cell viability by up-regulation in Bcl2 gene, a decrease in apoptosis by enhanced CDK2 gene expression and a decrease in cell cycle arrest at G0/G1 phase were also observed in SW579 cell lines transfected with silenced BTG2 gene. When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-κB pathway and the expression of BTG2. However, when treated with BMS-345541 and 131I, only the NF-κB pathway was suppressed. 131I suppressed cell proliferation, induced cell apoptosis, and promoted cell cycle arrest of thyroid cancer cells by up-regulating B-cell translocation gene 2-mediated activation of JNK/NF-κB pathways.
Descritores: Apoptose/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Radioisótopos do Iodo/uso terapêutico
Sistema de Sinalização das MAP Quinases
Proteínas de Neoplasias/genética
Neoplasias da Glândula Tireoide/tratamento farmacológico
-Linhagem Celular Tumoral
Radioisótopos do Iodo/farmacologia
Proteínas de Neoplasias/metabolismo
Reação em Cadeia da Polimerase
Neoplasias da Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/patologia
Limites: Seres Humanos
Responsável: BR1.1 - BIREME


  4 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-797890
Autor: Mai, TJ; Ma, R; Li, Z; Bi, SC.
Título: Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;49(11):e5620, 2016. graf.
Idioma: en.
Resumo: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a negative regulator of T cell activation, which competes with CD28 for B7.1/B7.2 binding, and which has a greater affinity. Fusion of specific antigens to extracellular domain of CTLA4 represents a promising approach to increase the immunogenicity of DNA vaccines. In this study, we evaluated this interesting approach for CTLA4 enhancement on prostate stem cell antigen (PSCA)-specific immune responses and its anti-tumor effects in a prostate cancer mouse model. Consequently, we constructed a DNA vaccine containing the PSCA and the CTLA-4 gene. Vaccination with the CTLA4-fused DNA not only induced a much higher level of anti-PSCA antibody, but also increased PSCA-specific T cell response in mice. To evaluate the anti-tumor efficacy of the plasmids, murine models with PSCA-expressing tumors were generated. After injection of the tumor-bearing mouse model, the plasmid carrying the CTLA4 and PSCA fusion gene showed stronger inhibition of tumor growth than the plasmid expressing PSCA alone. These observations emphasize the potential of the CTLA4-fused DNA vaccine, which could represent a promising approach for tumor immunotherapy.
Descritores: Antígenos de Neoplasias/uso terapêutico
Vacinas Anticâncer/uso terapêutico
Antígeno CTLA-4/uso terapêutico
Proteínas de Neoplasias/uso terapêutico
Plasmídeos/uso terapêutico
Neoplasias da Próstata/terapia
Vacinas de DNA/uso terapêutico
-Antígenos de Neoplasias/imunologia
Antígenos de Neoplasias/metabolismo
Vacinas Anticâncer/imunologia
Antígeno CTLA-4/genética
Antígeno CTLA-4/imunologia
Modelos Animais de Doenças
Proteínas Ligadas por GPI/imunologia
Proteínas Ligadas por GPI/metabolismo
Proteínas Ligadas por GPI/uso terapêutico
Proteínas de Neoplasias/imunologia
Proteínas de Neoplasias/metabolismo
Plasmídeos/genética
Neoplasias da Próstata/imunologia
Proteínas Recombinantes de Fusão/uso terapêutico
Vacinas de DNA/genética
Limites: Animais
Masculino
Camundongos
Responsável: BR1.1 - BIREME


  5 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-790389
Autor: Faria, André Murad.
Título: Papel do LIN28, uma proteína ligadora de RNAs, na tumorigênese adrenocortical / Role of LIN28, an RNA-binding protein, in adrenocortical tumorigenesis.
Fonte: São Paulo; s.n; 2014. [167] p. ilus, tab, graf.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Medicina para obtenção do grau de Doutor.
Resumo: INTRODUÇÃO: O carcinoma adrenocortical é uma neoplasia rara que carreia um prognóstico reservado. Recentemente, uma série de estudos demonstrou o potencial do perfil de miRNAs na diferenciação entre adenomas e carcinomas adrenocorticais, estratificação de risco e prognóstico. Entretanto, pouco se sabe ainda sobre a regulação pós-transcricional de miRNAs. Nesse contexto, o LIN28 é uma proteína ligadora de RNAs altamente conservada que surgiu como um modulador do let-7, uma importante família de miRNAs amplamente conhecida por seus efeitos supressivos tumorais. Além do let-7, o LIN28 também mostrou regular e ser regulado pelo mir-9, mir-30 e mir-125. OBJETIVOS: Analisar a expressão gênica e proteica do LIN28 em uma grande coorte de tumores adrenocorticais (TACs) de adultos e pediátricos, além de investigar a variação no número de cópias dos genes LIN28A e LIN28B e a expressão dos miRNAs regulatórios do LIN28 (família let-7, mir-9, mir-30 e mir-125) em um subgrupo desta coorte. MÉTODOS: A expressão proteica do LIN28 foi avaliada em um total de 266 TACs de adultos (78 adenomas e 188 carcinomas) e 44 pediátricos (35 clinicamente benignos e 9 clinicamente malignos). A expressão dos genes LIN28A e LIN28B foi avaliada em um subgrupo de 86 TACs adultos e pediátricos e a análise da variação no número de cópias destes genes em 58 TACs. O estudo de expressão das famílias dos miRNAs let-7, mir-9, mir-30 e mir-125 foi realizado em 28 carcinomas adrenocorticais de adultos. RESULTADOS: Em adultos, o gene LIN28A mostrou-se hiperexpresso em carcinomas agressivos quando comparado a adenomas [7,0 (0 a 174,3) vs. 3,6 (0 a 18,3); p = 0,006, respectivamente] e observou-se uma tendência a maior expressão quando comparados a carcinomas não agressivos [7,0 (0 a 174,3) vs. 7,1 (0 a 17,1); p = 0,092]. A expressão do LIN28B foi negativa na grande maioria (92%) dos TACs de adultos. Curiosamente, uma imunorreatividade fraca para o LIN28 foi significativamente associada com...

INTRODUCTION: Adrenocortical carcinoma is a rare neoplasm with overall poor prognosis. Recently, several studies demonstrated the potential of miRNA profiling in differentiating between adrenocortical adenomas and carcinomas, risk stratification and prognosis. Nevertheless, little is known about posttranscriptional regulation of miRNAs. LIN28 is a highly conserved RNA-binding protein that has emerged as a modulator of the processing of let-7, an important family of miRNAs widely known for its tumor-suppressive effects. Besides from let-7, LIN28 has also shown to regulate and be regulated by mir-9, mir-30 and mir-125. OBJECTIVES: To analyze LIN28 gene and protein expression in a large cohort of adult and pediatric adrenocotical tumors (ACTs), and investigate the copy number variation analysis for LIN28A and LIN28B genes and the expression of LIN28 regulatory microRNAs (let-7 family, mir-9, mir-30 e mir-125) in a subgroup of this cohort. METHODS: LIN28 protein expression was assessed in a total of 266 adult (78 adenomas and 188 carcinomas) and 44 pediatric ACTs (35 clinically benign and 9 clinically malignant). LIN28A and LIN28B gene expression was evaluated in a subgroup of 86 adult and pediatric ACTs and copy number variation analysis of these genes in 58 ACTs. The expression of let-7 family, mir-9, mir-30 and mir-125 was performed in 28 adult carcinomas. RESULTS: In adults, LIN28A gene was overexpressed in aggressive carcinomas when compared with adenomas [7.0 fold change (from 0 to 174.3) vs. 3.6 (from 0 to 18.3); p = 0.006, respectively] and a trend towards greaten expression when compared with non-aggressive carcinomas [7.0 (from 0 to 174.3) vs. 7.1 (from 0 to 17.1); p = 0.092]. LIN28B expression was undetectable in the great majority (92%) of adult ACTs. Surprisingly, weak LIN28 staining was significantly associated with reduced disease-free survival in this population (p = 0.01), but for overall survival only a trend was detectable (p= 0.117). In...
Descritores: Biomarcadores Tumorais/genética
Carcinogênese/genética
Carcinoma Adrenocortical/genética
Expressão Gênica
MicroRNAs/genética
Prognóstico
Proteínas de Ligação a RNA/metabolismo
Proteínas de Neoplasias/genética
Regulação Neoplásica da Expressão Gênica/genética
Sobrevida
Limites: Seres Humanos
Masculino
Feminino
Criança
Adulto
Responsável: BR66.1 - Divisão de Biblioteca e Documentação
BR66.1


  6 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-767051
Autor: Silva Júnior, Maurício Moreira da; Matheus, Wagner Eduardo; Garcia, Patrick Vianna; Stopiglia, Rafael Mamprim; Billis, Athanase; Ferreira, Ubirajara; Fávaro, Wagner José.
Título: Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells
Fonte: Int. braz. j. urol;41(5):849-858, Sept.-Oct. 2015. tab, graf.
Idioma: en.
Projeto: Estado de São Paulo.
Resumo: ABSTRACT Introduction and Objectives: Reactive Stroma (RStr) is observed in many human cancers and is related to carcinogenesis. The objectives of the present study were to stablish a relationship of the RStr microenvironment with prostate cancer (Pca) through a morphological and molecular characterization, and to identify a possible relationship between RStr with worse prognosis factors and occurrence of malignant prostatic stem cells. Materials and Methods: Forty prostatic samples were selected from men with Pca diagnosis submitted to radical prostatectomy; they were divided in two groups: Group-1 (n=20): samples without reactive stroma; Group-2 (n=20): samples of PCa with intense stroma reaction. Prostatic samples were evaluated for RStr intensity by Masson Trichromic stain and posteriorly submitted to histopathological and immunohistochemistry analysis for antigens: α-actin, vimentin, IGF-1, MMP-2, FGF-2, C-Myc, PSCA, AR, Erα and ERβ. Results: Reactive stroma with intense desmoplastic reactivity was significantly more frequent in intermediate (Gleason 7, 3+4) and high grade tumors (Gleason 7, 4+3). The group with intense stromal reactivity showed significant higher levels of Vimentin, IGF-1, MMP-2, FGF-2, C-Myc, PSCA and ERα. Conclusions: It can be concluded that RStr may be a predictive marker of Pca progression, since it was associated with increase of growth factors, imbalance of androgen and estrogen receptors and presence of malign prostatic stem cells.
Descritores: Adenocarcinoma/patologia
Células Epiteliais/patologia
Células-Tronco Neoplásicas/patologia
Neoplasias da Próstata/patologia
Células Estromais/patologia
-Actinas/análise
Adenocarcinoma/química
Antígenos de Neoplasias/análise
Biomarcadores Tumorais/análise
Progressão da Doença
Proteínas de Ligação a DNA/análise
Células Epiteliais/química
Receptor alfa de Estrogênio/análise
/análise
FIBROBLAST GROWTH FACTOR TEMEFOS/análise
Proteínas Ligadas por GPI/análise
Imuno-Histoquímica
Fator de Crescimento Insulin-Like I/análise
/análise
MATRIX METALLOPROTEINASE TEMEFOS/análise
Gradação de Tumores
Proteínas de Neoplasias/análise
Células-Tronco Neoplásicas/química
Neoplasias da Próstata/química
Células Estromais/química
Microambiente Tumoral
Fatores de Transcrição/análise
Vimentina/análise
Limites: Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Cavalcanti, Silvia Maria Baêta
Texto completo
Id: lil-763058
Autor: Koifman, Leandro; Ornellas, Paulo; Ornellas, Antonio Augusto; Pereira, Denise de Abreu; Zingali, Benedeta Russolina; Cavalcanti, Silvia Maria Baeta; Afonso, Larissa Alves; Sandim, Vanessa; Alves, Gilda.
Título: Proteomics analysis of tissue samples from patients with squamous cell carcinoma of the penis and positive to human papillomavirus
Fonte: Int. braz. j. urol;41(4):642-654, July-Aug. 2015. tab, graf.
Idioma: en.
Projeto: FAPERJ.
Resumo: ABSTRACTPurpose:The aim of this study was to identify possible protein biomarkers and/or candidates for therapeutic targets in tissues of patients with SCCP, infected by HPV, applying one dimensional electrophoresis (1DE), followed by direct mass spectrometry (MS) analysis.Materials and Methods:Tissues from 10 HPV positive patients with SCCP and from 10 patients with HPV negative non-tumorous penile foreskins were analyzed applying 1D electrophoresis, followed by analysis with direct mass spectrometry (MS).Results:Sixty-three different proteins were identified in the first group and 50 in the second group. Recognition was possible for 28 proteins exclusively detected in Group 1 and 21 proteins presented only in Group 2.Conclusion:Some proteins in the first group are directly involved in the development of other types of cancer, and therefore, suitable for analysis. Complement C3 protein is a strong candidate for evaluating SCCP patients.
Descritores: Carcinoma de Células Escamosas/química
Proteínas de Neoplasias/análise
Proteômica
Papillomaviridae/isolamento & purificação
Infecções por Papillomavirus/complicações
Neoplasias Penianas/química
-Biomarcadores Tumorais/análise
Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/virologia
/análise
COMPLEMENT CABATTOIRS/análise
Bases de Dados de Proteínas
Eletroforese
/isolamento & purificação
HUMAN PAPILLOMAVIRUS 1ABDOMINAL NEOPLASMS/isolamento & purificação
/isolamento & purificação
HUMAN PAPILLOMAVIRUS ABNORMALITIES, MULTIPLE/isolamento & purificação
Espectrometria de Massas
Dados de Sequência Molecular
Neoplasias Penianas/patologia
Neoplasias Penianas/virologia
Limites: Seres Humanos
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  8 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-762917
Autor: Meng, W.; Gu, T.; Gao, L. M.; Zong, Z. G.; Meng, L.; Fu, Z. Z.; Guo, L..
Título: Correlation of cadherin-17 protein expression with clinicopathological features and prognosis of patients with sporadic gastric cancer
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;48(12):1077-1086, Dec. 2015. tab, graf.
Idioma: en.
Resumo: This study aimed to explore the correlations between cadherin-17 (CDH17) protein expression and the clinicopathological features and prognosis of patients with sporadic gastric cancer (GC). Nine relevant studies of 1,960 patients were identified using electronic database searches supplemented with a manual search in strict accordance with inclusion and exclusion criteria. Statistical analyses were conducted using STATA 12.0 statistical software. Relative risks and 95% confidence intervals were determined, and Z test was used to measure the significance of the overall effect size. A total of nine eligible cohort studies were included in this meta-analysis. The expression of CDH17 in patients with diffuse GC was significantly higher than in those with intestinal-type GC. Moreover, the tumor depth of invasion differed significantly between patients with positive CDH17 (CDH17+) and negative CDH17 (CDH17-) GC. However, there were no significant differences between CDH17+ and CDH17- GC patients with respect to tumor node metastasis clinical stages, histological grades, or lymph node metastasis. Despite the differences in invasive depth, there was no significant difference in 5-year survival rates between CDH17+ and CDH17- GC patients. Our meta-analysis provides evidence that CDH17 protein expression may be associated with the development of GC, suggesting that CDH17 is an important biomarker that could be useful for the early diagnosis of GC. However, CDH17 levels do not appear to impact overall survival.
Descritores: Caderinas/metabolismo
Proteínas de Neoplasias/metabolismo
Neoplasias Gástricas/diagnóstico
-Intervalos de Confiança
Metástase Linfática
Invasividade Neoplásica
Prognóstico
Análise de Regressão
Taxa de Sobrevida
Neoplasias Gástricas/metabolismo
Neoplasias Gástricas/mortalidade
Neoplasias Gástricas/patologia
Limites: Seres Humanos
Tipo de Publ: Metanálise
Revisão
Responsável: BR1.1 - BIREME


  9 / 123 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-762910
Autor: Sá, V.K. de; Rocha, T.P.; Moreira, AL.; Soares, F.A.; Takagaki, T.; Carvalho, L.; Nicholson, A.G.; Capelozzi, V.L..
Título: Hyaluronidases and hyaluronan synthases expression is inversely correlated with malignancy in lung/bronchial pre-neoplastic and neoplastic lesions, affecting prognosis
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;48(11):1039-1047, Nov. 2015. tab, graf.
Idioma: en.
Projeto: CNPq; . FAPESP.
Resumo: We collected a series of 136 lung/bronchial and 56 matched lung parenchyma tissue samples from patients who underwent lung/bronchial biopsies and presented invasive carcinoma after lung surgery. The lung/bronchial samples included basal cell hyperplasia, squamous metaplasia, moderate dysplasia, adenomatous hyperplasia, severe dysplasia, squamous cell carcinoma and adenocarcinoma. Matched lung parenchyma tissue samples included 25 squamous cell carcinomas and 31 adenocarcinomas. Immunohistochemistry was performed to analyze for the distribution of hyaluronidase (Hyal)-1 and −3, and hyaluronan synthases (HAS)-1, −2, and −3. Hyal-1 showed significantly higher expression in basal cell hyperplasia than in moderate dysplasia (P=0.01), atypical adenomatous hyperplasia (P=0.0001), or severe dysplasia (P=0.03). Lower expression of Hyal-3 was found in atypical adenomatous hyperplasia than in basal cell hyperplasia (P=0.01) or moderate dysplasia (P=0.02). HAS-2 was significantly higher in severe dysplasia (P=0.002) and in squamous metaplasia (P=0.04) compared with basal cell hyperplasia. HAS-3 was significantly expressed in basal cell hyperplasia compared with atypical adenomatous hyperplasia (P=0.05) and severe dysplasia (P=0.02). Lower expression of HAS-3 was found in severe dysplasia compared with squamous metaplasia (P=0.01) and moderate dysplasia (P=0.01). Epithelial Hyal-1 and −3 and HAS-1, −2, and −3 expressions were significantly higher in pre-neoplastic lesions than in neoplastic lesions. Comparative Cox multivariate analysis controlled by N stage and histologic tumor type showed that patients with high HAS-3 expression in pre-neoplastic cells obtained by lung/bronchial biopsy presented a significantly higher risk of death (HR=1.19; P=0.04). We concluded that localization of Hyal and HAS in lung/bronchial pre-neoplastic and neoplastic lesions was inversely related to malignancy, which implied that visualizing these factors could be a useful diagnostic procedure for suspected lung cancer. Finalizing this conclusion will require a wider study in a randomized and prospective trial.
Descritores: Neoplasias Brônquicas/enzimologia
Carcinoma de Células Escamosas/enzimologia
Glucuronosiltransferase/metabolismo
Hialuronoglucosaminidase/metabolismo
Neoplasias Pulmonares/enzimologia
Proteínas de Neoplasias/metabolismo
Lesões Pré-Cancerosas/enzimologia
-Neoplasias Brônquicas/patologia
Carcinoma de Células Escamosas/patologia
Moléculas de Adesão Celular/análise
Hialuronoglucosaminidase/análise
Hiperplasia/enzimologia
Imuno-Histoquímica
Estimativa de Kaplan-Meier
Neoplasias Pulmonares/patologia
Análise Multivariada
Metaplasia/enzimologia
Prognóstico
Lesões Pré-Cancerosas/patologia
Índice de Gravidade de Doença
Estatísticas não Paramétricas
Limites: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  10 / 123 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-749652
Autor: Odashiro, Macanori; Hans Filho, Gunter; Pereira, Patricia Rusa; Castro, Ana Rita Coimbra Motta; Stief, Alcione Cavalheiro; Pontes, Elenir Rose Jardim Cury; Odashiro, Alexandre Nakao.
Título: Melanoma inhibitory activity in Brazilian patients with cutaneous melanoma
Fonte: An. bras. dermatol;90(3):327-332, May-Jun/2015. tab, graf.
Idioma: en.
Resumo: Abstract BACKGROUND: Melanoma inhibitory activity is a protein secreted by melanoma cells and has been used as a tumor marker. Increased Melanoma inhibitory activity serum levels are related to metastatic disease or tumor recurrence. Currently there are no studies on Melanoma inhibitory activity and cutaneous melanoma involving Brazilian patients. OBJECTIVE: To evaluate the performance and feasibility of measuring Melanoma inhibitory activity levels in Brazilian patients with cutaneous melanoma. METHODS: Blood was obtained from ten patients with proved metastatic cutaneous melanoma (Group 1), 15 patients resected for cutaneous melanoma without metastasis (Group 2) and 5 healthy donors (Group 3). Melanoma inhibitory activity was measured using a commercially available ELISA kit. RESULTS: There was a statistically significant difference of Melanoma inhibitory activity levels between patients with and without metastasis (p=0.002), and between patients with metastasis and healthy donors (p=0.002). There was no difference between patients without metastasis and healthy donors (p=0.443). CONCLUSION: Melanoma inhibitory activity is a tumor marker for cutaneous melanoma and the Melanoma inhibitory activity-ELISA test can be easily performed. Patients with metastasis have increased Melanoma inhibitory activity serum levels when compared to patients without metastasis and healthy donors. .
Descritores: Proteínas da Matriz Extracelular/sangue
Melanoma/sangue
Proteínas de Neoplasias/sangue
Neoplasias Cutâneas/sangue
-Brasil
Estudos de Casos e Controles
Ensaio de Imunoadsorção Enzimática
Estudos de Viabilidade
Melanoma/patologia
Melanoma/secundário
Metástase Neoplásica
Valores de Referência
Reprodutibilidade dos Testes
Estatísticas não Paramétricas
Neoplasias Cutâneas/patologia
Neoplasias Cutâneas/secundário
Limites: Adulto
Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde